TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Autologous Blood, Corticosteroid, and Their Combined Injection for Treating Lateral Epicondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1-Patients with LE whose complaints persisted for more than 3 months~Exclusion Criteria:~1. Patients with a history of recent trauma,~2. Congenital or neuromuscular disease or abnormality of the upper limb~3. Previous upper limb surgery,~4. History of rheumatic disease,~5. History of cervical disc pathology or carpal tunnel syndrome~6. Systemic corticosteroid treatment~7. Any previous local injection treatment~8. Patients with a history of previous allergic reaction towards local anesthetics and corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Autologous Blood Injection Mixed With Local Anesthetic (Type: ACTIVE_COMPARATOR): Autologous Blood Injection group were administered 1ml of autologous venous blood mixed with 2ml of 2% prilocaine HCl(Priloc %2,Vem,Turkey) subcutaneously.
- Corticosteroid Injection Mixed With Local Anesthetic (Type: ACTIVE_COMPARATOR): Corticosteroid Injection category were given 1ml of 40 mg methylprednisolone acetate(Prednol-L 40mg,Mustafa Nevzat,Turkey) mixed with 2ml of 2% prilocaine HCl(Priloc %2,Vem,Turkey) subcutaneously.
- Combined Injection Mixed With Local Anesthetic (Type: ACTIVE_COMPARATOR): Combined Injection group received a mixture containing 1ml each of autologous venous blood and 40mg methylprednisolone acetate(Prednol-L 40mg,Mustafa Nevzat,Turkey), along with 1ml of 2% prilocaine HCl(Priloc %2,Vem,Turkey) subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paracervical Block for Pain Associated With Laminaria Insertion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women between the ages of 18-49 years~* Desiring surgical termination of pregnancy or surgical management of a fetal demise~* Treatment plan involves cervical preparation with laminaria~* Participant able to provide informed consent in English and willing to participate in the study~Exclusion Criteria:~* Unable to read/speak/understand English~* Contraindications to receiving lidocaine

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Paracervical Block with lidocaine (Type: ACTIVE_COMPARATOR): A paracervical block will be done prior to the placement of laminaria with 1% lidocaine and sodium bicarbonate.
- Sham paracervical block (Type: SHAM_COMPARATOR): A sham block will be done prior to the placement of laminaria using a capped needle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes mellitus on diet/exercise therapy and metformin as monotherapy~Exclusion Criteria:~* Patients with type 1 diabetes mellitus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- P (Type: PLACEBO_COMPARATOR): None
- E (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Music on the Sedative Use During Coronary Angioplasty

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient needs a coronary angiography~* Patient gives verbal consent to participation in the study.~Exclusion Criteria:~* Patient aged less than 18 years at time of enrollment~* Patient doesn't like music for cultural reason~* Patient with serious psychiatric disorders~* Patient with not paired deafness or paired one with devices that are incompatible with wearing a headset.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): The control group will undergo coronary angiography without music intervention.
- Music therapy (Type: EXPERIMENTAL): The intervention group will also undergo coronary angiography and will administer music therapy between 10 minutes prior to the beginning of the procedure until its end.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent.~2. Age:18～75 (when informed consent is obtained)，male or female.~3. Non-hypovolemic and non acute hyponatremia with a Serum sodium \< 135mEq/L before randomization. (main underlying diseases include CHF, hepatic cirrhosis with edema, SIADH and others)~4. In-patient subjects.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* FOR THE MAIN TRIAL, NN5401-3594:~* Type 1 diabetes mellitus for at least 12 months~* Ongoing daily treatment with insulin (in a basal bolus regimen, premix insulin regimen, self mix regimen) for at least 12 months~* HbA1c 7.0-10.0% (both inclusive)~* BMI (Body Mass Index) below or equal to 35.0 kg/m\^2~* FOR THE EXTENSION TRIAL, NN5401-3645:~* The subject must have completed the six-month treatment period in trial NN5401-3594~Exclusion Criteria:~* FOR THE MAIN TRIAL, NN5401-3594:~* Treatment with other insulin regimens than insulin in a basal bolus regimen/premix insulin regimen/self mix regimen within 3 months~* Cardiovascular disease within the last 6 months~* Uncontrolled treated/untreated severe hypertension~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements~* Cancer and medical history of cancer~* FOR THE EXTENSION TRIAL, NN5401-3645:~* Anticipated significant lifestyle changes during the trial~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegAsp OD (Type: EXPERIMENTAL): None
- IDet (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven intracranial glioblastoma multiforme with pathologic or imaging confirmation of tumor progression or regrowth after failure of two previous treatment regimens~* Initial low-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma~* History and physical exam, including neurologic examination, within 4 weeks prior to registration~Exclusion Criteria:~• Warfarin or LMW heparin patients must have no active bleeding or pathological condition that carries a high risk of bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Fractionated Radiosurgery and Bevacizumab (Type: EXPERIMENTAL): FRS and Bev followed by Bev combined either Irinotecan or Temozolamide or Carboplatin or Etoposide until progression
- Bev with Chemo (Type: ACTIVE_COMPARATOR): Bev combined either Irinotecan or Temozolomide or Carboplatin or Etoposide until progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Injectable Platelet Rich Fibrin on Healing and Patient Satisfaction Following Laser Gingival Depigmentation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female with age range from 16 to 45 years old.~* Systemically free from any disease as evidenced by the health questionnaire guided by modified Cornell medical index (Pendleton et al., 2004).~* Gingival hyperpigmentation on maxillary and mandibular labial keratinized gingiva score 3 (Dummett et al., 1964).~* Patient with thick gingival phenotype (\>1.5mm) (Claffey and Shanley, 1986).~Exclusion Criteria~* Pregnant and lactating women.~* Smokers.~* Gingival pigmentation associated with occupational Hazards.~* Patients with missing anterior teeth.~* Patients with any metallic restoration related to anterior teeth or undergoing orthodontic treatment.~* Vulnerable groups (prisoners, handicapped and orphans).

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- (LASER WITH I-PRF) (Type: EXPERIMENTAL): Eight sites that were treated with laser method for gingival depigmentation, followed by intra-mucosal field injection of I-PRF
- (LASER WITHOUT I-PRF) (Type: ACTIVE_COMPARATOR): Eight sites that were treated with laser technique for gingival depigmentation only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Efficacy of Magnetic Resonant Therapy (MRT) in PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to adhere to the treatment schedule and all required study visits.~* Any non-Active Duty Military are included.~* PCL-M \> 45~* Primary diagnosis of Posttraumatic Stress Disorder rendered by the Clinician Administered PTSD Scale (CAPS)~Exclusion Criteria:~* Individuals diagnosed by the Investigator with the following conditions (current unless otherwise stated): History of open skull traumatic brain injury. History of clinically significant seizure disorder.~* Individuals with a clinically defined neurological disorder including, but not limited to: Any condition likely to be associated with increased intracranial pressure. Space occupying brain lesion. History of cerebrovascular accident. Cerebral aneurysm.~* EEG abnormalities that indicate risk of seizure, i.e., abnormal focal or general slowing or spikes during the EEG recording.~* Any type of rTMS treatment within 3 months prior to the screening visit.~* Currently under antipsychotic medication treatment.~* Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head, excluding the mouth, which cannot be safely removed.~* Clinically significant abnormality or clinically significant unstable medical condition that in the Investigator's judgment might pose a potential safety risk to the subject or limit interpretation of the trial results.~* Clinically significant medical illness, including any uncontrolled thyroid disorders, hepatic, cardiac, pulmonary and renal malfunctioning.~* Any condition which in the judgment of the investigator would prevent the subject from completion of the study.~* Inability to acquire a clinically satisfactory EEG/ECG on a routine basis.~* Grossly abnormal electrolyte or cell blood count panels suggestive of other pathology at study initiation.~* Active Duty Military are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Sham Stimulation (Type: SHAM_COMPARATOR): Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase only) using a sham device. Sham device mimics the same noise and sensation of active treatment.
- Active sTMS (Type: ACTIVE_COMPARATOR): Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase) and 2 additional weeks for all subjects (open label) with Synchronized Transcranial Magnetic Stimulation (sTMS), using an active device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Evaluating the Efficacy of Resultz Lice and Egg Elimination Kit on Pediatric and Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have active head lice infestations (at least 1 live louse and eggs)~* Good general health based on medical history~* Each subject has to be consented~Exclusion Criteria:~* Subjects with any condition that would compromise the study~* History of irritation or sensitivity to pediculicides or hair care products~* Subjects with cranial or facial implants~* Subjects who have received radiation within the last 6 months~* Subjects with history of heart disease~* Subjects with history of epilepsy or seizure disorders~* Subjects with neuro-stimulator or pacemaker~* Subject with hair that staff cannot comb~* Subject previously treated in study in last 30 days~* Use of lice treatment in past 2 weeks~* Subject unable to sense pain~* Subject unable to communicate pain

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Resultz Lice and Egg Elimination Kit (Type: EXPERIMENTAL): Resultz combing solution, head lice comb and instructions for use in a kit: apply liquid then comb out for 1 hour
- Placebo Lice and Egg Elimination Kit (Type: PLACEBO_COMPARATOR): 20% glycerin combing solution, comb and instructions for use in a kit: apply liquid then comb out for 1 hour

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: California Transport Cooling Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Term or near-term infants with gestational age ≥35 weeks who meet institutional criteria for use of therapeutic hypothermia and in whom the decision has been made to perform cooling during transport.~Exclusion Criteria:~* Presence of a congenital or lethal chromosomal anomaly~* Decision to not provide full intensive care~* Refusal to consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Hours
- Healthy Volunteers: f

Study Arms:
- Control (standard practice) (Type: ACTIVE_COMPARATOR): Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
- Device (servo-regulated cooling) (Type: EXPERIMENTAL): Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-stroke Neural Plasticity With Atomoxetine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic stroke patients~* Single stroke~* Chronic (more than 6 months after from stroke)~* At least 21 years old, but there is no upper age range for this project.~* Participants NOT able to extend the affected metacarpophalangeal joints at least 10° and the wrist 20°.~Exclusion Criteria:~* History of head injury with loss of consciousness~* History of severe alcohol or drug abuse~* History of psychiatric illness~* Unstable cardiac dysrhythmia~* High blood pressure (systolic pressure \>160 mm Hg and/or diastolic pressure \>100 mm Hg)~* History of myocardial infarction or unstable angina~* Pregnancy~* Glaucoma, history of hypersensitivity or idiosyncrasy to sympathomimetic drugs.~* Subjects using drugs suspected of interfering with plasticity, such as MAOI, alpha-adrenergic antagonists, benzodiazepines, muscarinic receptor antagonists, dopaminergic antagonists, or other neuroleptics within 3 months of recruitment.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine with motor training (Type: EXPERIMENTAL): 40 mg atomoxetine paired with task-oriented therapy for 10 consecutive weekdays
- Placebo with motor training (Type: PLACEBO_COMPARATOR): Placebo capsules paired with task-oriented therapy for 10 consecutive weekdays

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol for the Treatment of Postpartum Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Vaginal delivery~* Postpartum hemorrhage due to suspected uterine atony~* Depending on study group: administration of prophylactic uterotonics in third stage of labor~Exclusion Criteria:~* Known allergy to misoprostol or other prostaglandin~* C-section for current delivery

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Misoprostol (Type: EXPERIMENTAL): 800 mcg sublingual misoprostol
- Oxytocin (Type: ACTIVE_COMPARATOR): 40 IU Oxytocin IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Middle School to High School Transition Project: Depression and Substance Abuse Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At-risk for substance abuse, academic failure, and depression~* Enrolled in eighth grade in Seattle Public Schools~* English-speaking~Exclusion Criteria:~* Score above the clinical cutoff on the Youth Self Report Aggressive subscale

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Brief Intervention (Type: ACTIVE_COMPARATOR): Brief Intervention: After each youth and parent completed baseline questionnaires the youth participated in a 1 on 1 standardized clinical follow-up with a trained clinician (blind to study condition) to review areas of concern, based on questionnaire responses including stressors at school, home, and with peers, level of support available and how to access support. The teen and clinician then planned a feedback call to parents, allowing teens to shape requests for support from parents as well as understand exactly what information would be shared with parents. Feedback call to parents reviewed concerns and made recommendations for services as needed. A similar procedure was followed after each assessment for all participants who indicated a risk of clinical depression or self-harm.
- CAST-T/HSTS (Type: EXPERIMENTAL): The CAST-T/HSTS condition combined the Brief Intervention and 12 school based small group sessions which taught skills to enhance personal control (to manage depression, anger, stress), self-esteem, decision making and interpersonal communications. HSTS skills groups were held in the spring of 8th grade with 4 one-on-one booster sessions delivered to the students as 9th graders by HSTP leaders; parents also participated in 4 sessions. HSTS objectives are: 1) to increase the acquisition of coping skills competencies by teaching and practicing strategies taught; 2) to increase social support resources by building a supportive network; 3) to increase the youth's engagement in positive social activities; and 4) to motivate parents to increase their support via parent educational sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete